Skip to main content

Advertisement

Fig. 8 | Experimental Hematology & Oncology

Fig. 8

From: Early vs. late MRD response- and risk-based treatment intensification of childhood acute lymphoblastic leukemia: a prospective pilot study from Saudi Arabia

Fig. 8

The 5-year overall survival (a), event-free survival (b), and cumulative incidence of relapse (c) based on minimal residual disease (MRD) transition from day-15 to day-29 of induction. N → N, day 15 MRD negative (< 0.01%) and day-29 MRD negative (< 0.01%). Y → N, day-15 MRD positive (≥ 0.01%) but day-29 MRD negative (< 0.01%). Y → Y, day-15 MRD positive (≥ 0.01%) and day-29 MRD positive (≥ 0.01%). Survival outcome differences were statistically significant (p < 0.05)

Back to article page